Substance · official US FDA label
Flurbiprofène (flurbiprofen)
8 medicines listed on Vimpia contain it, alone or combined. Below, the official US FDA label for flurbiprofen, unchanged.
Want to buy it?
Trouver shows the pharmacies near you that have it right now, and their prices. The reservation pages are in French.
This is a US label.
The official US FDA label for flurbiprofen (published as FLURBIPROFEN SODIUM), effective April 14, 2026, describes products sold in the United States. The medicine sold in DR Congo may differ in strength, form or approved uses: ask a pharmacist or a doctor.
Official US FDA label for flurbiprofen
Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. The full label on DailyMed.
Uses
INDICATIONS AND USAGE Flurbiprofen sodium ophthalmic solution is indicated for the inhibition of intraoperative miosis.
Dosage
US dosage, for products sold in the United States. For a medicine bought in DR Congo, follow its box, its leaflet or your pharmacist.
DOSAGE AND ADMINISTRATION A total of four (4) drops of flurbiprofen sodium ophthalmic solution should be administered by instilling one (1) drop approximately every 1/2 hour beginning 2 hours before surgery.
Warnings and precautions
WARNINGS With some nonsteroidal anti-inflammatory drugs, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that flurbiprofen sodium ophthalmic solution may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. There is the potential for cross-sensitivity to acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
Side effects
ADVERSE REACTIONS Transient burning and stinging upon instillation and other minor symptoms of ocular irritation have been reported with the use of flurbiprofen sodium ophthalmic solution. Other adverse reactions reported with the use of flurbiprofen sodium ophthalmic solution include: fibrosis, hyphema, miosis, mydriasis, and ocular hyperemia. Increased bleeding tendency of ocular tissues in conjunction with ocular surgery has also been reported (see Warnings ). To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Medicines that contain it
Names as they are sold. A medicine without an English page links to its French page.
- ANTADYS 100 mg, comprimé pelliculé
- CEBUTID 100 mg, comprimé enrobé
- CEBUTID 50 mg, comprimé enrobé
- CEBUTID LP 200 mg, gélule à libération prolongée
- Flurifen 100 mg, comprimé pelliculé
- OCUFEN 0,12 mg/ 0,4 ml, collyre en récipient unidose
- STREFEN 8,75 mg ORANGE SANS SUCRE, pastille édulcorée à l'acésulfame potassique
- STREFEN 8,75 mg, pastille
Sources
- ●Labels: U.S. Food and Drug Administration, openFDA (public domain). Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. DailyMed.
- ●English names of substances: RxNorm, U.S. National Library of Medicine.
- ●Marketing authorizations: register of the ACOREP, DR Congo.
- ●Essential medicines: national list of essential medicines of DR Congo (LNME).
- ●Composition: public medicines database of France (BDPM), ANSM, open licence.
Public information, for reference only: it does not replace the advice of a pharmacist or a doctor. Vimpia writes nothing about how to use a medicine and translates nothing: the label is the US FDA's, unchanged; names, composition and authorizations come from the official sources above.